Journal
CURRENT ONCOLOGY REPORTS
Volume 20, Issue 7, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-018-0696-8
Keywords
Chemotherapy-induced cardiomyopathy; Chemotherapy-induced cardiotoxicity; Pharmacogenetics of cancer; Pharmacogenomics of cancer
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL133491] Funding Source: NIH RePORTER
- NHLBI NIH HHS [K08 HL133491] Funding Source: Medline
Ask authors/readers for more resources
The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended. There is no recommendation regarding testing in adults. There is clear evidence pointing to the role of pharmacogenetics and pharmacogenomics in cardiotoxicity susceptibility to chemotherapeutic agents. Larger scale studies are needed to further identify susceptibility markers and to develop pharmacogenomics-based risk profiling to improve quality of life and life expectancy in cancer survivors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available